Persistence of Benzodiazepines After Initiation in Patients Prescribed Long-term Opioids: Retrospective Cohort Study

Abstract Importance Patients prescribed long-term opioids are often co-prescribed benzodiazepines, which heighten overdose risk. Objective To assess the persistence of new opioid-benzodiazepine co-prescriptions and identify patient characteristics associated with persistent co-prescription. Design Retrospective cohort study. Setting Data from the Optum Labs Data Warehouse, which includes de-identified medical and pharmacy claims and enrollment records for commercial and Medicare Advantage enrollees across the United States. Participants U.S. adults with a new benzodiazepine prescription (≥ 3 days' supply) from July 1, 2016 to December 31, 2021, who were prescribed opioids for ≥ 80% of days during a 6-month baseline period and no benzodiazepines in the prior year. Outcome Measures Days of overlapping opioid and benzodiazepine prescriptions during 30-day periods for up to 1 year of follow-up, classified as 0, 1–10, 11–24, and ≥ 25 days. Results The study included 32,815 patients with mean follow-up of 9.9 months. Initial benzodiazepine prescriptions were written by primary care physicians (47.9%), psychiatrists (5.2%), or other specialties (46.9%). At month 12, 25.7% had persistent opioid-benzodiazepine overlap. Compared to patients with 1–10 days of overlap in month 1, those with 11–24 days had significantly increased odds of higher overlap at month 12 [adjusted odds ratio (aOR) for 11–24-day overlap at month 12: 3.58 (95% CI: 3.03–4.22); aOR for ≥ 25-day overlap: 3.65 (3.07–4.33)]; those with ≥ 25 days of month 1 overlap had even greater risk [aOR for 11–24 day overlap at month 12: 4.48 (3.85–5.22); aOR for ≥ 25 day overlap: 9.73 (8.37–11.32)]. Patients whose initial benzodiazepine prescriber was a psychiatrist were significantly more likely to have ≥ 25 days’ overlap in month 1 (aOR vs. primary care physician: 2.45 [2.10–2.85]). Conclusions Persistent opioid-benzodiazepine co-prescription is common following benzodiazepine initiation in patients prescribed long-term opioids, and greater days of initial overlap increases risk of long-term co-prescription.

Authors

Publication Details

Journal
Journal of General Internal Medicine
Published
2026-11-10
DOI
https://doi.org/10.1007/s11606-026-10985-4
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Persistence of Benzodiazepines After Initiation in Patients Prescribed Long-term Opioids: Retrospective Cohort Study

Shao‐You Fang, James J. Gasper, Iraklis Erik Tseregounis, Joshua J. Fenton et al.
Journal of General Internal Medicine
Opioid Use Disorder Treatment
article

Persistence of Benzodiazepines After Initiation in Patients Prescribed Long-term Opioids: Retrospective Cohort Study

Shao‐You Fang, James J. Gasper, Iraklis Erik Tseregounis, Joshua J. Fenton, Jeremy DeMartini, Stephen G. Henry, Susan Stewart, Marykate Miller
article en

Abstract

Abstract Importance Patients prescribed long-term opioids are often co-prescribed benzodiazepines, which heighten overdose risk. Objective To assess the persistence of new opioid-benzodiazepine co-prescriptions and identify patient characteristics associated with persistent co-prescription. Design Retrospective cohort study. Setting Data from the Optum Labs Data Warehouse, which includes de-identified medical and pharmacy claims and enrollment records for commercial and Medicare Advantage enrollees across the United States. Participants U.S. adults with a new benzodiazepine prescription (≥ 3 days' supply) from July 1, 2016 to December 31, 2021, who were prescribed opioids for ≥ 80% of days during a 6-month baseline period and no benzodiazepines in the prior year. Outcome Measures Days of overlapping opioid and benzodiazepine prescriptions during 30-day periods for up to 1 year of follow-up, classified as 0, 1–10, 11–24, and ≥ 25 days. Results The study included 32,815 patients with mean follow-up of 9.9 months. Initial benzodiazepine prescriptions were written by primary care physicians (47.9%), psychiatrists (5.2%), or other specialties (46.9%). At month 12, 25.7% had persistent opioid-benzodiazepine overlap. Compared to patients with 1–10 days of overlap in month 1, those with 11–24 days had significantly increased odds of higher overlap at month 12 [adjusted odds ratio (aOR) for 11–24-day overlap at month 12: 3.58 (95% CI: 3.03–4.22); aOR for ≥ 25-day overlap: 3.65 (3.07–4.33)]; those with ≥ 25 days of month 1 overlap had even greater risk [aOR for 11–24 day overlap at month 12: 4.48 (3.85–5.22); aOR for ≥ 25 day overlap: 9.73 (8.37–11.32)]. Patients whose initial benzodiazepine prescriber was a psychiatrist were significantly more likely to have ≥ 25 days’ overlap in month 1 (aOR vs. primary care physician: 2.45 [2.10–2.85]). Conclusions Persistent opioid-benzodiazepine co-prescription is common following benzodiazepine initiation in patients prescribed long-term opioids, and greater days of initial overlap increases risk of long-term co-prescription.

Journal of General Internal Medicine
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon